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MDCTAbstract Objective: To evaluate MDCT perfusion role in HCC local therapy response.
Patients and methods: Post radiofrequency ablation and trans-arterial chemoembolization 14
(88%) male and 2 (12%) female HCC patients; with the mean age, 55.75 ± 10.6 years underwent
follow-up hepatic CT perfusion. The hepatic arterial and portal venous perfusions (HAP and
HPP, ml/min/100 ml) and hepatic perfusion index (HPI%) were indicated using the color coded
maps to assess the effects of local therapy on hepatic perfusion values.
Results: The post local treatment CTP of the recurrent tumor conﬁrmed relative increased HAP
and HPI and reduced PVP relative to the background values of the cirrhotic hepatic parenchyma.
The recurrent HCC post-treatment CTP including HAP is 71 ± 12.19, the PVP is 25.5 ± 8.66 and
HPI is 52.5 ± 11.9. The post local-treatment CTP of the necrosis conﬁrmed relative decreased HAP
and HPI and increased PVP. The post-treatment necrosis CTP including HAP is 23 ± 10.39, the
PVP is 34.75 ± 11.5 and HPI is 29 ± 16.51. The CTP sensitivity is 75%, speciﬁcity 50% and
P-value <0.05.
Conclusion: CTP is a promising non-invasive technique assessing the efﬁcacy, predicting early
response to local treatment therapies and monitoring tumor recurrence. It assesses the degree of
post therapy tumor perfusion especially the degree of arterialization.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide accounting for 90% of primary malignantneoplasm of the liver (1). It is responsible for more than
500,000 deaths every year globally (2). Limitations of tradi-
tional imaging response criteria, such as World Health Organi-
zation (WHO) criteria or Response Evaluation Criteria in
Solid Tumors (RECIST) for evaluating targeted therapies have
been widely established (3). Recently, tumor density measure-
ment and tissue biopsy coupled with micro vessel density (MVD)
assessment have been explored as potential new methods for
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be limited due to prevalence of underlying cirrhosis and coag-
ulopathy (1) (see Fig. 1–3).
Volume Perfusion MDCT (CTP) is a promising method for
calculating hepatic arterial and portal blood ﬂow, including
microcirculation, using a color-encoded display of parameters
obtained from the liver time density curve, with iodine contrast
agent (3).
CTP allows for quantiﬁcation of perfusion in absolute units
at high spatial resolution. This method is reportedly useful for
evaluation of severity of hepatic ﬁbrosis associated, assessment
of hepatic tumor perfusion and prediction of tumor response
to therapies (4). Wang et al. (5) and Ng et al. (6) reported
improved monitoring of hepatic perfusion changes after radio-
logical interventions.
However, some problems remain with using CTP, such as
long breath holding for portal ﬂow measurement, limited cran-
iocaudal scan range, separation of arterial and portal bloodFig. 1 70 years old Male patient with elevated AFP, and left hepatic
Follow-up Post RFA Triphasic CT and CTP revealed recurrent ecce
coagulative necrosis (G, H, I, J, K and L). CTP of the tumor conﬁrme
PF. CTP of the post RFA coagulative necrosis revealed relative decreﬂow, standardization of analytic methods, and unknown
effects of extrahepatic factors (4).
This study was aimed to evaluate role of CTP in HCC local
therapy response.
2. Patients and methods
2.1. Patients
Between February 2014 and November 2015, a total of 16
patients were subjected to this study, and out of them 14
(88%) were male patients and 2 (12%) were female, with the
mean age, 55.75 ± 10.6 years and age between 41 and 72
years. This retrospective study monitored the patients with
HCC undergoing local treatment in the terms of RFA and
TACE. The local Institutional Review Board approved the
study and all patients gave their written consent.lobe lateral segment ill-deﬁned focal HCC (A, B, C, D, E and F).
ntric tumor activity and at the superior extent of the post RFA
d relative increased HAP/AF and HPI/PI as well as reduced PVP/
ased HAP/AF and HPI/PI as well as increased PVP/PF.
Fig. 2 72 years old Male patient with elevated AFP, and right hepatic lobe segment 7 focal HCC underwent TACE. Follow-up Triphasic
CT (A and B) and CTP (C, D, E and F) revealed recurrent tumor activity. CTP of the tumor conﬁrmed relative increased HAP/AF and
HPI/PI as well as reduced PVP/PF.
Fig. 3 54 years old Male patient with right hepatic lobe segment 7 focal HCC underwent RFA. Follow-up Triphasic CT (A and B) and
CTP (C, D, E and F) revealed post RFA coagulative necrosis with relative decreased HAP/AF HPI/PI and increased PVP/PF.
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and post TACE or RFA. Suspected or conﬁrmed HCC histo-
logically was proven in (7) patients or based on imaging
features in 8 (50%) patients together with elevated serum alpha
feto proteine level >200 in 10 (62.5%) patients. Exclusion
criteria were contraindication of IV contrast media administra-
tion including elevated serum creatinine and contrast allergy.
Patients were weighed (P130 kg) because of machine weight
limit and for better image quality demonstration.
All patients had liver cirrhosis according to Child Pugh crite-
ria, and they are Child A. Underlying cause of cirrhosis in the
patients wasHepatitis C-virus. None of our patients give history
of alcohol intake or proved to have Hepatitis B-virus infection.2.2. MDCT perfusion (CTP) imaging protocol
All examinations were performed in Police Authority Nasr
City Hospital using 320-row CT scanner (Aquilion ONE
320-MDCT, Toshiba medical systems corporation, Japan).
The CT protocol consisted of a non-enhanced abdominal
low-dose CT (40 mAs, 100 kV) to localize the porta hepatis.
Liver CTP parameters were as follows: (80 kV, 100 mAs). At
ﬁrst test bolus technique was performed and subsequently
the perfusion measurements were started accordingly. A
50 mL of non-ionic water soluble contrast media was injected
followed by a saline ﬂush.
Table 1 Triphasic CT ﬁndings.
Conventional triphasic CT Paired diﬀ. Paired sample t-test
Mean ±SD Mean ±SD t P-value
Liver density (cirrhosis) 64.00 12.54
Tumor density (pre RFA/TACE) 122.75 41.33 58.75 42.64 3.897 0.006
Tumor density (Recurrence) 98.00 39.68 34.00 45.46 2.115 0.072
Tumor necrosis density 27.00 3.46 28.00 12.70 4.409 0.022
Tumor size (pre-treatment) 4.50 1.20
Recurrent tumor size (post treatment) 3.25 0.89 1.25 1.39 2.546 0.038
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Axial and coronal reformatted images were obtained for perfu-
sion analysis using Vitrea external workstation. Regions of
interest (ROI) were placed in the abdominal aorta at the level
of the celiac axis for the arterial input function (AIF). Addi-
tionally ROIs in the portal vein, spleen and tumor were placed
to generate time-density curves (TDC). Subsequently, dual-
input single compartment model method was used for separate
calculation of arterial (HAP/AF) and portal-venous (PVP/PF)
blood ﬂow to the liver and tumor. HAP and PVP values are
given in (ml/100 mL) tissue/minute and HPI (%) is indicated
using the color coded maps.2.3.1. Statistical analysis
Data were analyzed using Statistical Program for Social
Science (SPSS) version 22.0. Quantitative data were expressed
as mean ± standard deviation (SD). Qualitative data were
expressed as frequency and percentage.
The following tests were done:
Independent-samples t-test of signiﬁcance was used when
comparing between two means.
 Chi-square (X2) test of signiﬁcance was used in order to
compare proportions between two qualitative parameters.
 Receiver operating characteristic (ROC curve) analysis was
used to ﬁnd out the overall predictivity of parameter in and
to ﬁnd out the best cutoff value with detection of sensitivity
and speciﬁcity at this cutoff value.
1. Sensitivity = (true +ve)/[(true +ve) + (false ve)].
2. Speciﬁcity = (true ve)/[(true ve) + (false +ve)].
3. PPV = (true +ve)/[(true +ve) + (false +ve)].
4. NPV = (true ve)/[(true ve) + (false ve)].
 Probability (P-value)
1. P-value < 0.05 was considered signiﬁcant.
2. P-value < 0.001 was considered as highly signiﬁcant.
3. P-value > 0.05 was considered insigniﬁcant.
3. Results
The triphasic CT and CTP were performed pre and post treat-
ment including RFA in 12 (75%) patients and TACE in 4
(25%) patients, for evaluation of morphological triphasic CT
and functional CTP criteria of HCC (Table 1).
The pre-treatment triphasic CT ﬁndings include Hepatic
cirrhosis parenchyma density (64 ± 12.54 HU), pre-RFA/TACE tumor density (122.75 ± 41.33 HU), and tumor size
(4.5 ± 1.2 cm). The tumor was visible in 8 (50%) patients. It
is ill-deﬁned in the other 8 (50%) patients (Table 1).
The pre-treatment CTP of tumor conﬁrmed increased HAP
and HPI and reduced PVP relative to the cirrhotic parenchyma
values. The pre-treatment CTP ﬁnding of the cirrhotic
parenchyma including HAP is 18.5 ± 3.74, the PVP is 94.75
± 15.52 and HPI is 16.75 ± 4.03. The HCC pre-treatment
HAP is 104 ± 10.28, the PVP is 13.25 ± 10.78 and HPI is
91.50 ± 7.87 (Table 2).
The post RFA/TACE Triphasic CT ﬁndings include recur-
rent tumor density (98 ± 39.68 HU) and recurrent tumor size
(3.25 ± 0.89 cm). It is visible in 6 (37.5%) patients. In addition
the post treatment necrosis density is 37.2 ± 20.2.
The post local-treatment CTP of the recurrent tumor
conﬁrmed relative increased HAP and HPI and reduced PVP
relative to the background values of the cirrhotic hepatic par-
enchyma. The recurrent HCC post-treatment CTP including
HAP is 71 ± 12.19, the PVP is 25.5 ± 8.66 and HPI is 52.5
± 11.9. The post local-treatment CTP of the necrosis con-
ﬁrmed relative decreased HAP and HPI and increased PVP.
The post-treatment necrosis CTP including HAP is 23
± 10.39, the PVP is 34.75 ± 11.5 and HPI is 29 ± 16.51.
The Triphasic CT scanning sensitivity (40%), speciﬁcity
(33.3%), positive (50%) and negative (25%) predictive values
as well as the accuracy (37.5%) and P-value (>0.05). The
CTP sensitivity (75%), speciﬁcity (50%), positive (60%) and
negative (66.7%) predictive values as well as the accuracy
(62.5%) and P-value (<0.05) (Table 3).
4. Discussion
The liver is the most challenging organ for perfusion imaging,
due to its unique dual vascular supply (8) and considerable res-
piratory motion (7). Our study not agrees with Spira et al. (7),
who reported that the liver is probably the most challenging
organ for CTP measurement and interpretation due to consid-
erable diaphragmatic movement during breathing, as the
motion correction and the application of ﬁlters allow recon-
struction of good-quality images even with free-breathing of
the patient during scanning. Triphasic CT is the main diagnos-
tic tool in tumor evaluation, including diagnosis, staging, or
monitoring of therapies because of the relatively low cost
and wide availability. CTP may augment standard therapeutic
assessment in clinical trials and in the clinical environment. By
use of functional imaging techniques to assess the response to
therapy, it would be possible to achieve earlier discrimination
between responders and non-responders (8).
Table 2 CTP HCC ﬁndings.
CT Perfusion Paired diﬀ. Paired sample t-test
Mean ±SD Mean ±SD t P-value
HAP (Cirrhosis) 18.50 3.74
HAP (pre RFA/TACE) 104.00 10.28 85.50 10.73 22.54 <0.001
HAP (Tumor recurrence) 71.00 12.19 54.00 13.83 7.81 0.004
HAP (Tumor necrosis) 23.00 10.39 25.75 21.93 3.32 0.013
PVP (Cirrhosis) 94.75 15.52
PVP (pre RFA/TACE) 13.25 10.78 81.50 25.42 9.07 <0.001
PVP (Tumor recurrence) 25.50 8.66 83.00 1.15 143.76 <0.001
PVP (Tumor necrosis) 34.75 11.50 62.50 52.01 3.40 0.011
HPI (Cirrhosis) 16.75 4.03
HPI (pre RFA/TACE) 91.50 7.87 74.75 11.32 18.67 <0.001
HPI (Tumor recurrence) 52.50 11.90 38.50 13.03 5.91 0.010
HPI (Tumor necrosis) 29.00 16.51 5.25 17.03 0.87 0.412
Table 3 Triphasic CT and CTP parameters.
Treatment conventional
triphasic CT
Treatment necrosis CT
perfusion
Positive 8 12
Negative 8 4
Sensitivity 40% 75%
Speciﬁcity 33.3% 50%
+PV 50% 60%
PV 25% 66.67%
Accuracy 37.5% 62.5%
P-value >0.05 (NS) <0.05 (S)
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(50%) of patients at pre-treatment triphasic CT scanning.
These results are explained by Takayasu et al. (9), who
reported that 44% of early HCCs could not be detected due
to iso-attenuation in triphasic CT.
The liver diseases show alterations of vascular physiology
which are easily recognized via CTP. CTP is deﬁned as ‘‘real”
blood ﬂow through a volume of tissue per time and therefore
constitutes a very different parameter from the well-known
concept of blood velocity, which is used for the evaluation of
ﬂow dynamics in large vessels. CTP measures temporal
changes in tissue density after IV contrast injection using
repeated CT scans of the volume being analyzed. Thus density
measurements include contrast material contained in the intra
as well as the extra vascular space (7).
The liver is the most challenging organ for CTP interpreta-
tion due to considerable respiratory movement and dual blood
supply. Importantly separate calculation of HAP and PVP by
placement of ROIs in PV and spleen is possible due to simul-
taneous perfusion of both organs via hepatic and splenic arter-
ies. In focal liver lesions CTP facilitates the tumor vascularity
and permeability analysis. This overcomes the limitations of
slice-dependent assessment and may prove beneﬁcial in ther-
apy monitoring of focal tumors (10).
Importantly, CTP enables distinction of tumor thrombus
from non-vascularized thrombosis. CTP aids in the detection
characterization as well as response assessment of tumors to
therapy, including therapy-related complications (e.g. hemor-
rhage, liver parenchymal necrosis) (7).
CTP has been used for early identiﬁcation of tumor recur-
rence after regional image-guided therapies of HCC. Ourresults agree with Mahnken et al. (11) who reported the useful-
ness of quantitative volumetric arterial enhancement fraction
color mapping for the early detection of recurrent tumor
after RFA. They observed that the tumor arterial perfusion
values were signiﬁcantly higher when compared with liver
parenchyma.
Our results demonstrated that the post treatment Triphasic
CT ﬁndings include recurrent tumor density (98 ± 39.68 HU)
and recurrent tumor size (3.25 + 0.89). It is visible in 6
(37.5%) patients. In addition the post treatment necrosis density
is 27 ± 3.46. The post local-treatment CTP of the recurrent
tumor conﬁrmed relative increased HAP and HPI and reduced
PVP relative to the background values of the cirrhotic hepatic
parenchyma. The recurrent HCC post-treatment CTP includ-
ing HAP is 71 ± 12.19, the PVP is 25.5 ± 8.66 and HPI is
52.5 ± 11.9. The post local-treatment CTP of the necrosis
conﬁrmed relative decreased HAP and HPI and increased
PVP. The post-treatment necrosis CTP including HAP is 23
± 10.39, the PVP is 34.75 ± 11.5 and HPI is 29 ± 16.51.
In addition, our results are in partial agreement with
Meijerink et al. (12), who reported that marginal lesions with
high HAP (>50 mL/min/100 g) and low hepatic portal perfu-
sion (<10 mL/min/100 g) represented recurrent tumor tissue
after RFA with an increased risk for local RFA–site tumor
recurrence. Furthermore, areas of recurrent tumors on CTP
images were well matched with hot spots on PET/CT images.
Ippolito et al. (13) and Choi et al. (14) reported that CTP
parameters obtained 1 week after TACE did not help predict
future recurrence. The recurrence eventually occurred at
4 weeks after TACE. The recurrent HCC within TACE-
treated areas had signiﬁcantly higher HAP, and HPI than
the lipiodolized area or the cirrhotic parenchyma.
Early identiﬁcation of tumor recurrence around RFA
defect or lipiodolized nodule is sometimes challenging with
conventional CT because tumor recurrence around RFA
defect can be confused with reactive hyperemia around RFA
area and because HCC recurrence around lipiodolized nodule
can be obscured by beam hardening artifacts that occurred due
to high attenuation of accumulated lipiodol. CTP may play an
important role in these aspects, being noteworthy in patient
management. However, further studies with larger study pop-
ulations are again needed to assess the role of CT perfusion in
diagnosing tumor recurrence early (15).
This study has several limitations. First, our study suffers
from a relative short term study and limited number of
692 A.M. Enite, H. Rabeepatients. Second, there was histological proof of HCC in 8
(50%) patients due to the presence of elevated serum AFP level
>200 in 10 (62%) patients, who were enrolled as a result of
typical imaging ﬁndings in a background of cirrhotic liver.
This inclusion criteria is in partial agreement with Kaufmann
et al. (1), who stated that they include newly occurred liver
lesions presenting typical imaging ﬁndings (wash-in and/or
wash-out kinetics) suggestive for e.g. early HCC as their ethic
board approval included only HCC-typical lesions amenable
for local therapy. Third, we did not document the radiation
exposure dose; however, the radiation exposure in our research
might be increased. This is conﬁrmed by Kaufmann et al. (1)
who stated that mean radiation exposure for liver perfusion
measurements was 7 mSv. It is explained by Wang et al. (5)
who reported that the wide craniocaudal scan range and rela-
tive large number of scans increased volume computed tomo-
graphic dose index. The radiation dose can be lowered in the
future combining with further optimized perfusion imaging
protocols. Fourth, we only applied dual-input single compart-
ment mode to calculate perfusion values and we are not using
deconvolution or maximal slope methods. However this is not
consistent with Wang et al. (5) and Kanda et al. (4) who used
maximal slope mode, due to the relative simple underlying
principle; is the dominate one in the ﬁeld of liver perfusion
measurement and is widely applied in many studies. Further
studies are required to conﬁrm our ﬁndings and to better
understand segmental variances of hepatic parenchyma, in
both normal and pathological conditions, Wang et al. (5).
Conclusion
Our study proved that CTP is a promising technique assessing
the efﬁcacy, predicting early response to local therapies and
monitoring tumor recurrence. It assesses the degree of post
therapy tumor perfusion especially its arterialization. It is
adjunct to hepatic conventional triphasic imaging techniques.
It enables distinction of tumor thrombus from non-
vascularized thrombosis.
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